Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to prevent transplant complications

NCT ID NCT07359859

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study tests whether switching to the drug ruxolitinib after a stem cell transplant can better prevent chronic graft-versus-host disease (GVHD) compared to standard treatment. About 40 adults with blood cancers who are in remission will receive either a medium dose of cyclophosphamide followed by ruxolitinib, or a full dose of cyclophosphamide alone. The goal is to see which approach reduces severe GVHD and improves survival one year after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ruxolitinib (a drug that reduces inflammation) and cyclophosphamide (a chemotherapy drug)
What this could lead to
If successful, this could offer a better way to prevent chronic graft-versus-host disease after stem cell transplants, reducing long-term complications.
What could go wrong
This is a small, early-phase pilot study with only 40 participants, so results may not apply broadly. The drugs also carry risks like infections and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)

    RECRUITING

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

    RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    RECRUITING

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.